Recent Finacing
Recent Raise
Audentes Therapeutics develops and commercializes AAV gene therapies for rare diseases, advancing clinical programs (AT001 XLMTM, AT002 Pompe, AT003 CASQ2‑CPVT), with in-house GMP manufacturing and pipeline expansion.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors